Morgan Stanley Starts Pacific Shuanglin Bio-pharmacy at Overweight With 37 Yuan Price Target

12:13 AM EDT, 05/27/2024 (MT Newswires) -- Morgan Stanley Starts Pacific Shuanglin Bio-pharmacy at Overweight With 37 Yuan Price Target Price (RMB): ¥26.18, Change: ¥-0.52, Percent Change: -1.95%

MT NewswiresMay 26 23:13

Pacific Shuanglin Bio-pharmacy's Unit Gets Nod to Trial Intravenous Human Immunoglobulin

Pacific Shuanglin Bio-pharmacy's (SHE:000403) unit, Guangdong Shuanglin Biopharmaceutical, will conduct clinical trails on its intravenous human immunoglobulin after obtaining approval of China's Nati

MT NewswiresMay 23 02:58

Express News | Pailin Biotech announced that its wholly-owned subsidiary has obtained a notice of approval for clinical trials of intravenous human immunoglobulin (10%) drugs.

BreakingsMay 22 05:27

Yang Feng, shareholder of Pailin Biotech (000403.SZ), completed a reduction of 5.9985 million shares

Zhitong Finance App News, Pailin Biotech (000403.SZ) announced that Yang Feng, the shareholder of the company, reduced his holdings of the company's shares by a total of 5.9985 million shares, accounting for 0.82% of the total share capital. The implementation of this holdings reduction plan has been completed.

Zhitong FinanceMay 10 07:19

Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License

Pacific Shuanglin Bio-pharmacy's (SHE:000403) subsidiary Jixi Donghai Pacific Plasma Apheresis obtained a plasmapheresis license from health authorities in Heilongjiang province, China, according to a

MT NewswiresMay 9 04:47

Pailin Biotech (000403.SZ): Guangdong Shuanglin Phase II Project is expected to be put into operation in the second half of 2025, and the annual production capacity will increase to 1,500 tons

Gelonghui, May 9, 丨 Pailin Biotech (000403.SZ) held a performance briefing on May 7, 2024. Regarding “the expected increase in production capacity after the Guangdong Shuanglin production workshop construction project is put into operation,” the company replied that the Guangdong Shuanglin Phase II project is expected to be put into operation in the second half of 2025, and the annual production capacity will increase to 1,500 tons.

Gelonghui FinanceMay 9 03:49